This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVO

About ABRYSVO

Efficacy ProfileImmunobridgingSafety ProfileDosing, Storage, & ReconstitutionPatient ProfilesOrder ABRYSVO

Order ABRYSVO

Order ABRYSVORefer ABRYSVOAccess & Support

Access & Support

Health Plan CoverageRequest a RepVaccine LocatorMaterialsVideos
Prescribing InformationIndicationsPatient SiteMaternal
Patient ProfilesABRYSVO®: CDC recommended for adults aged 75+ and adults aged 50-74 who are at increased risk of severe RSV disease1[This expanded RSV recommendation in adults aged 50-59 at increased risk is not final until endorsed by the CDC Director.]The risk to your vulnerable patients from RSV is real: Protect them with ABRYSVO this RSV seasonTake every opportunity to protect more of your eligible patients today Risk Conditions LoadingReferencesRisk calculation (RSV-associated hospitalization rate per 100,000) results come from CDC studies based on community-dwelling adults over the age of 50 with and without chronic medical conditions.4Data from RSVVaxView as of April 5, 2025.2CAD=coronary artery disease; CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; ICU=intensive care unit; RSV=respiratory syncytial virus.Related ContentRelated ContentRelated ContentOrder ABRYSVOLoadingVaccine LocatorLoading

Related Content

Related ContentRelated ContentRelated ContentOrder ABRYSVOLoadingVaccine LocatorLoading

Related Content

Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
Stay Informed
 Receive Updates About ABRYSVO    Register NowLoading Request a Pfizer Sales Representative  Connect NowLoading

Explore a range of resources related to ABRYSVO, including videos, information about upcoming events, and more.

View ResourcesLoading
References:Britton A, Melgar M, Surie D. Evidence to recommendations framework (EtR): RSV vaccination in adults aged 50-59 years. Centers for Disease Control and Prevention. Published April 16, 2025. Accessed April 16, 2025. https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/06-Melgar-Surie-adult-rsv-508.pdfCenters for Disease Control and Prevention. Respiratory syncytial virus (RSV) vaccination coverage and intent for vaccination, adults 75 years and older and adults 60–74 years with high-risk conditions, United States. December 3, 2024. Accessed December 11, 2024. https://www.cdc.gov/rsvvaxview/dashboard/index.htmlPatton ME. Epidemiology of respiratory syncytial virus hospitalizations in adults – RSV-NET. Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. Published October 25, 2003. Accessed April 28, 2025. https://stacks.cdc.gov/view/cdc/134689Woodruff RC. Chronic conditions as risk factors for RSV-associated hospitalization. Centers for Disease Control and Prevention. Presented at: Advisory Committee on Immunization Practices; February 29, 2024. Accessed March 17, 2025. https://www.cdc.gov/acip/downloads/slides-2024-02-28-29/03-RSV-Adults-Woodruff-508.pdf

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2025 Pfizer Inc. All rights reserved.

PP-A1G-USA-2315
IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
Please click here for full Prescribing Information.
Important Safety Information
  • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
  • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
  • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
  • Appropriate medical treatment must be available in case of an anaphylactic reaction
  • Syncope (fainting) may occur in association with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
  • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
  • Vaccination with ABRYSVO may not protect all vaccine recipients
  • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions
were fatigue (15.7%), headache (12.9%), pain at the injection site (10.7%), and muscle pain (10.2%)
  • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
  • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions
were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)
  • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO versus 4.4% placebo) and neonatal jaundice (7.2% ABRYSVO versus 6.7% placebo) were observed
Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Please see full Prescribing Information for ABRYSVO.IndicationsABRYSVO is a vaccine indicated for:
  • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
     
  • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
     
  • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367